Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC)

MLA

Giovanna Casili, et al. “Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC).” Cancers; Volume 15; Issue 10; Pages: 2796, May 2023. EBSCOhost, https://doi.org/10.3390/cancers15102796.

APA

Giovanna Casili, Sarah Adriana Scuderi, Marika Lanza, Alessia Filippone, Deborah Mannino, Raffaella Giuffrida, Cristina Colarossi, Marzia Mare, Anna Paola Capra, Federica De Gaetano, Marco Portelli, Angela Militi, Salvatore Cuzzocrea, Irene Paterniti, & Emanuela Esposito. (2023). Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers; Volume 15; Issue 10; Pages: 2796. https://doi.org/10.3390/cancers15102796

Chicago

Giovanna Casili, Sarah Adriana Scuderi, Marika Lanza, Alessia Filippone, Deborah Mannino, Raffaella Giuffrida, Cristina Colarossi, et al. 2023. “Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC).” Cancers; Volume 15; Issue 10; Pages: 2796, May. doi:10.3390/cancers15102796.